Physician profile
Sin-Ching Chiu
NPI 1205814472
$1,748.34
in general payments reported to CMS, 2019-2025
20 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2022: $186 · 2024: $356 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.76 | 2025 | Caplyta |
| Novo Nordisk INC | $196.53 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $189.33 | 2022-2025 | Farxiga, Airsupra |
| Abbvie INC. | $169.96 | 2024-2025 | |
| Indivior INC. | $152.62 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $144.01 | 2024-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $119.17 | 2022-2025 | |
| Exact Sciences Corporation | $96.16 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $94.00 | 2025 | |
| Braeburn INC. | $58.44 | 2024-2025 | Brixadi |
| Alkermes, INC. | $51.29 | 2025 | Aristada, Vivitrol, Lybalvi |
| Viatris Specialty LLC | $38.03 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $37.28 | 2025 | Evkeeza |
| Mylan Specialty L.P. | $29.64 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $20.54 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $19.80 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $19.12 | 2025 | Austedo Xr |
| Actelion Pharmaceuticals US, INC. | $15.97 | 2025 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $15.16 | 2025 | Rexulti |
| Amgen INC. | $13.53 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sin-Ching Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.